AlphAIalphai — Financial news for AI agents
Business WireMAY 54 min read$DTIL

Precision BioSciences Reports First Quarter 2026 Financial Results and Provides Business Update

Precision BioSciences announced its first-quarter 2026 financial results, highlighting ongoing clinical progress for its gene editing programs PBGENE-HBV and PBGENE-DMD. The company reported a cash balance of $125.8 million, expected to fund operations and data milestones through 2028. Key advancements include expanding the ELIMINATE-B trial for PBGENE-HBV and activating the first clinical site for the FUNCTION-DMD trial for PBGENE-DMD, alongside positive updates from partnered programs.

Original reporting
Business Wire
Published May 5, 2026, 11:00 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 5, 2026, 11:30 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefFinancial news
Primary signal
$DTIL
Bullish
high confidence
Mentioned
$DTIL
alphai data visualization · based on Business Wire
Decision brief

The 30-second read

$DTILBullishMed
01

Why it matters

The company's progress suggests increased investor confidence and potential valuation growth.

02

Market read

The news is highly relevant to biotech investors, especially those focused on gene editing and therapeutic advancements.

03

What to watch

Regulatory hurdles or funding challenges may impact future progress.

Timing: Immediate to short-term (next 1-3 months)

Background

Precision BioSciences is advancing its gene editing programs with significant clinical milestones and a solid cash position.

Company-level read

Ticker impact

$DTILBullishHigh confidence
Context

Primary focus due to recent financial results and clinical progress.

Expected impact

Moderate upward movement expected over the next 1-3 months.

Evidence & confidence

Strong financial position and clinical advancements support positive sentiment; however, biotech stocks are inherently volatile.

Market effects

Sector

Potential positive impact on biotech and gene therapy sectors due to advancements.

Regional

Limited regional impact; primarily relevant to US biotech markets.

Global

Moderate; biotech innovations can influence global health markets.

Counterpoint

What could challenge this read

Potential delays or setbacks in clinical trials could negate positive outlook.

Key entities

  • Company
    Precision BioSciences

    Biotech firm specializing in gene editing technologies.

  • Program
    PBGENE-HBV

    Gene editing therapy targeting hepatitis B virus.

  • Program
    PBGENE-DMD

    Gene editing therapy for Duchenne Muscular Dystrophy.

Read at source← All news

Related articles

AUG 20
$DTILMedAI 8/10

iECURE, Inc.: iECURE to Present Clinical Data from Ongoing OTC-HOPE Trial of ECUR-506 in Neonatal-Onset Ornithine Transcarbamylase Deficiency at SSIEM Annual Symposium

iECURE, Inc. announced that data from its OTC-HOPE clinical trial of ECUR-506 for neonatal-onset OTC deficiency will be presented at the SSIEM Annual Symposium. The presentation will include safety and metabolic control data. iECURE is a clinical-stage genome editing company, and Precision BioSciences (DTIL) is involved through its ARCUS nuclease technology.

finanznachrichten.de2 min
AUG 6
$DTILMed

PRECISION BIOSCIENCES INC (DTIL): Results of Operations and Financial Condition

PRECISION BIOSCIENCES INC (DTIL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q22026earningsrelease_final.htm EX-99.1 Document Exhibit 99.1 Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update - First clinical biopsy evidence of direct cccDNA elimination from ongoing Phase 1 ELIMINATE-B trial; PBGENE-HB

SEC EDGAR 8-K6 min
MAY 27
$DTILHighAI 9/10

Precision BioSciences Shows First Evidence Of CccDNA Elimination In Hepatitis B Patients; Stock Up

Precision BioSciences (DTIL) reported first clinical biopsy evidence from its ELIMINATE-B study that PBGENE-HBV can eliminate and inactivate hepatitis B cccDNA. The company said cccDNA transcripts fell 10-fold after two doses, with remaining cccDNA showing indels that disrupt viral polymerase. It also reported pgRNA as a biomarker and durable HBsAg declines up to a year; 38 doses in 16 patients showed no dose-limiting toxicities.

rttnews.com6 min
AUG 20
$PGNYHigh

This fertility benefit business is set to boom. Buy the stock now, Wells Fargo says

Wells Fargo initiated coverage of Progyny with an overweight rating and $37 price target, implying 45% upside. The analyst cited demographic trends, corporate wellness focus, and healthcare innovation as drivers. Progyny's market share growth, global expansion, and new offerings were highlighted. Nine of 11 analysts rate the stock a buy or strong buy, with shares up 13% over the past year.

cnbc.com2 min
AUG 20
$COFMed

Bank of America sends message on Capital One stock

Capital One (COF) reported mixed July data, with healthy credit trends but slower domestic card portfolio growth. Bank of America analyst Mihir Bhatia maintained a Buy rating and $253 price target, citing solid credit performance. COF's card loans grew 1.92% YoY, down from June's 2.58%. The company is integrating Discover, acquired in May 2025, with CEO Richard Fairbank reporting progress. Q2 net income was $3 billion, and revenue increased 4% sequentially to $15.9 billion.

yahoo.com2 min